VALN
Valneva SE
NASDAQ · Healthcare · Biotechnology · FR
$6.89
−2.41%Year over year
Reported trailing growth
- Revenue
- -26.9%
- EBITDA
- —
- EBIT
- —
- EPS
- -97.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +12.4%
- EBITDA
- +84.9%
- EPS
- +53.7%
Three-year CAGR
- Revenue
- -21.5%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +31.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026